A phase I trial of the γ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).

被引：3
|
作者：
Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, Thomas Jeff
Steward, William P.
Hagemann, Thorsten
Venugopal, Balaji
Tuveson, David A.
Hategan, Mirela
Anthoney, David Alan
Farmer, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah E. R.
Jodrell, Duncan Ian
机构：
[1] Univ Cambridge, Cambridge Res Inst, Canc Res UK, Cambridge, England
[2] Cambridge Univ NHS Fdn Trust, Addenbrookes Hosp, Dept Oncol, Cambridge, England
[3] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge, England
[4] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[5] Univ Leicester, Dept Oncol, Leicester, Leics, England
[6] Univ London, Barts Canc Inst, London, England
[7] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Cold Spring Harbor Labs, New York, NY USA
[9] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[10] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[11] Canc Res UK, Drug Dev Off, London, England
[12] Canc Res UK, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4116
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC)
    Kundranda, Madappa N.
    Propper, David
    Ritch, Paul S.
    Strauss, James
    Hidalgo, Manuel
    Gillmore, Roopinder
    Sarangarajan, Rangaprasad
    Narain, Niven R.
    Kiebish, Michael A.
    Rodrigues, Leonardo O.
    Granger, Elder
    Ramanathan, Ramesh
    Alistar, Angela Tatiana
    Bui, Lynne A.
    Chawla, Sant P.
    Niewiarowska, Anna A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors
    Doss, H. H.
    Jones, S. F.
    Infante, J. R.
    Spigel, D. R.
    Willcutt, N.
    Lamar, R.
    Barton, J.
    Keegan, M.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma
    Kamgar, Mandana
    Khan, Husain Yar
    Aboukameel, Amro
    Bannoura, Sahar F.
    Chung, Brian Y.
    Szabo, Aniko
    Li, Yiwei
    Al Hallak, Mohammed Najeeb
    Philip, Philip A.
    George, Ben
    Christians, Kathleen K.
    Evans, Douglas B.
    Tsai, Susan
    Erickson, Beth
    Goldberg, John M.
    Azmi, Asfar S.
    Hall, William A.
    CANCER RESEARCH, 2024, 84 (07)
  • [34] A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma
    Chiorean, Elena G.
    Dragovich, Tomislav
    Hamm, John
    Barrios, Carlos H.
    Gorini, Carlos F.
    Langmuir, Virginia K.
    Kroll, Stewart
    Jung, Donald T.
    Tidmarsh, George T.
    Loehrer, Patrick J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 111 - 116
  • [35] Phase I trial of gemcitabine in patients with advanced pancreatic cancer
    Okada, S
    Ueno, H
    Okusaka, T
    Ikeda, M
    Furuse, J
    Maru, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (01) : 7 - 12
  • [36] Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.
    O'Hara, Mark H.
    Gallagher, Maryann
    Teitelbaum, Ursina R.
    Giantonio, Bruce J.
    Damjanov, Nevena
    Loaiza-Bonilla, Arturo
    Amaravadi, Ravi K.
    Heitjan, Daniel F.
    Vasilevskaya, Irina
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Laheru, Dan
    De Jesus-Acosta, Ana
    Velculescu, Victor E.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial
    Baretti, Marina
    Danilova, Ludmila
    Durham, Jennifer N.
    Betts, Courtney B.
    Cope, Leslie
    Sidiropoulos, Dimitrios N.
    Tandurella, Joseph A.
    Charmsaz, Soren
    Gross, Nicole
    Hernandez, Alexei
    Ho, Won Jin
    Thoburn, Chris
    Walker, Rosalind
    Leatherman, James
    Mitchell, Sarah
    Christmas, Brian
    Saeed, Ali
    Gaykalova, Daria A.
    Yegnasubramanian, Srinivasan
    Fertig, Elana J.
    Coussens, Lisa M.
    Yarchoan, Mark
    Jaffee, Elizabeth
    Azad, Nilofer S.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [38] Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
    Jeong, J. H.
    Yoo, C.
    Kim, K-P.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 263 - 263
  • [39] Prospective trial of preoperative FOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma (PDAC): Report of early endpoints.
    Shahda, Safi
    House, Michael Garrett
    Zyromski, Nicholas J.
    Sehdev, Amikar
    Cramer, Harvey M.
    Flynn, Janet
    Akisik, Fatih
    Ceppa, Eugene P.
    Schmidt, C. Max
    Nakeeb, Attila
    Lin, Jingmei
    Perkins, Susan M.
    Burney, Heather
    O'Neil, Bert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
    Beatty, Gregory L.
    Torigian, Drew A.
    Chiorean, E. Gabriela
    Saboury, Babak
    Brothers, Alex
    Alavi, Abass
    Troxel, Andrea B.
    Sun, Weijing
    Teitelbaum, Ursina R.
    Vonderheide, Robert H.
    O'Dwyer, Peter J.
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6286 - 6295
12345